154 related articles for article (PubMed ID: 37717659)
21. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs.
Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Ishihara H; Kikuchi H
Int J Pharm; 2012 Oct; 436(1-2):636-43. PubMed ID: 22850293
[TBL] [Abstract][Full Text] [Related]
22. Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus.
Henry CE; Wang YY; Yang Q; Hoang T; Chattopadhyay S; Hoen T; Ensign LM; Nunn KL; Schroeder H; McCallen J; Moench T; Cone R; Roffler SR; Lai SK
Acta Biomater; 2016 Oct; 43():61-70. PubMed ID: 27424083
[TBL] [Abstract][Full Text] [Related]
23. Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells.
Shimizu T; Mima Y; Hashimoto Y; Ukawa M; Ando H; Kiwada H; Ishida T
Immunobiology; 2015 Oct; 220(10):1151-60. PubMed ID: 26095176
[TBL] [Abstract][Full Text] [Related]
24. Pegfilgrastim (PEG-G-CSF) Induces Anti-polyethylene Glycol (PEG) IgM via a T Cell-Dependent Mechanism.
Elsadek NE; Emam SE; Abu Lila AS; Shimizu T; Ando H; Ishima Y; Ishida T
Biol Pharm Bull; 2020; 43(9):1393-1397. PubMed ID: 32879214
[TBL] [Abstract][Full Text] [Related]
25. Anti-PEG scFv corona ameliorates accelerated blood clearance phenomenon of PEGylated nanomedicines.
Zhang Z; Chu Y; Li C; Tang W; Qian J; Wei X; Lu W; Ying T; Zhan C
J Control Release; 2021 Feb; 330():493-501. PubMed ID: 33383098
[TBL] [Abstract][Full Text] [Related]
26. Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture.
Lin YC; Chen BM; Tran TTM; Chang TC; Al-Qaisi TS; Roffler SR
J Control Release; 2023 Feb; 354():354-367. PubMed ID: 36641121
[TBL] [Abstract][Full Text] [Related]
27. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
Ishida T; Atobe K; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
[TBL] [Abstract][Full Text] [Related]
28. Ex-vivo/in-vitro anti-polyethylene glycol (PEG) immunoglobulin M production from murine splenic B cells stimulated by PEGylated liposome.
Abu Lila AS; Ichihara M; Shimizu T; Ishida T; Kiwada H
Biol Pharm Bull; 2013; 36(11):1842-8. PubMed ID: 24189428
[TBL] [Abstract][Full Text] [Related]
29. Impact of anti-PEG antibody affinity on accelerated blood clearance of pegylated epoetin beta in mice.
Chang TC; Chen BM; Wu JY; Cheng TL; Roffler S
Biomed Pharmacother; 2022 Feb; 146():112502. PubMed ID: 34891120
[TBL] [Abstract][Full Text] [Related]
30. Accelerated blood clearance and hypersensitivity by PEGylated liposomes containing TLR agonists.
Stavnsbjerg C; Christensen E; Münter R; Henriksen JR; Fach M; Parhamifar L; Christensen C; Kjaer A; Hansen AE; Andresen TL
J Control Release; 2022 Feb; 342():337-344. PubMed ID: 34973307
[TBL] [Abstract][Full Text] [Related]
31. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes.
Ishida T; Harada M; Wang XY; Ichihara M; Irimura K; Kiwada H
J Control Release; 2005 Jul; 105(3):305-17. PubMed ID: 15908032
[TBL] [Abstract][Full Text] [Related]
32. Treatment-induced and Pre-existing Anti-peg Antibodies: Prevalence, Clinical Implications, and Future Perspectives.
Gaballa SA; Shimizu T; Ando H; Takata H; Emam SE; Ramadan E; Naguib YW; Mady FM; Khaled KA; Ishida T
J Pharm Sci; 2024 Mar; 113(3):555-578. PubMed ID: 37931786
[TBL] [Abstract][Full Text] [Related]
33. Repeated injection of PEGylated solid lipid nanoparticles induces accelerated blood clearance in mice and beagles.
Zhao Y; Wang L; Yan M; Ma Y; Zang G; She Z; Deng Y
Int J Nanomedicine; 2012; 7():2891-900. PubMed ID: 22745552
[TBL] [Abstract][Full Text] [Related]
34. Accelerated Clearance of Ultrasound Contrast Agents Containing Polyethylene Glycol is Associated with the Generation of Anti-Polyethylene Glycol Antibodies.
Fix SM; Nyankima AG; McSweeney MD; Tsuruta JK; Lai SK; Dayton PA
Ultrasound Med Biol; 2018 Jun; 44(6):1266-1280. PubMed ID: 29602540
[TBL] [Abstract][Full Text] [Related]
35. Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy.
Yang Q; Ma Y; Zhao Y; She Z; Wang L; Li J; Wang C; Deng Y
Int J Nanomedicine; 2013; 8():1257-68. PubMed ID: 23576868
[TBL] [Abstract][Full Text] [Related]
36. A higher dose of PEGylated gold nanoparticles reduces the accelerated blood clearance phenomenon effect and induces spleen B lymphocytes in albino mice.
Abu-Dief AM; Alsehli M; Awaad A
Histochem Cell Biol; 2022 Jun; 157(6):641-656. PubMed ID: 35157114
[TBL] [Abstract][Full Text] [Related]
37. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage.
Abu Lila AS; Kiwada H; Ishida T
J Control Release; 2013 Nov; 172(1):38-47. PubMed ID: 23933235
[TBL] [Abstract][Full Text] [Related]
38. Impact of Pre-Existing or Induced Anti-PEG IgM on the Pharmacokinetics of Peginterferon Alfa-2a (Pegasys) in Mice.
Elsadek NE; Hondo E; Shimizu T; Takata H; Abu Lila AS; Emam SE; Ando H; Ishima Y; Ishida T
Mol Pharm; 2020 Aug; 17(8):2964-2970. PubMed ID: 32519877
[TBL] [Abstract][Full Text] [Related]
39. Pseudo-anaphylaxis to Polyethylene Glycol (PEG)-Coated Liposomes: Roles of Anti-PEG IgM and Complement Activation in a Porcine Model of Human Infusion Reactions.
Kozma GT; Mészáros T; Vashegyi I; Fülöp T; Örfi E; Dézsi L; Rosivall L; Bavli Y; Urbanics R; Mollnes TE; Barenholz Y; Szebeni J
ACS Nano; 2019 Aug; 13(8):9315-9324. PubMed ID: 31348638
[TBL] [Abstract][Full Text] [Related]
40. Anti-PEG IgM production and accelerated blood clearance phenomenon after the administration of PEGylated exosomes in mice.
Emam SE; Elsadek NE; Abu Lila AS; Takata H; Kawaguchi Y; Shimizu T; Ando H; Ishima Y; Ishida T
J Control Release; 2021 Jun; 334():327-334. PubMed ID: 33957196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
